|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The needle-free drug delivery devices market is expected to register a CAGR of 6.5% over the forecast period.
The COVID-19 outbreak greatly impacted every aspect of the medical device industry, including the needle-free drug delivery devices market. At the outbreak of the COVID-19 pandemic, most pharmaceutical companies and governments worked toward offering efficient medical treatment to COVID-19 patients, and needle-free drug delivery devices were expected to play a vital role in that context as these devices were used in the administration of drugs and vaccines. For instance, in July 2022, research was conducted by the University of Queensland in partnership with Vaxxas, testing the Hexapro SARS-CoV-2 spike vaccine using the Vaxxas high-density microarray patch (HD-MAP) technology, and the results showed that the patch was far more effective at neutralizing COVID-19 variants. Such device advancements in the administration of COVID-19 vaccines will have a positive impact on the market growth rate over the coming years.
Needle-free injection systems are novel ways to introduce various medicines to patients without piercing the skin with a conventional needle. The needle-free drug delivery devices market is being driven by factors such as the rising prevalence of chronic diseases and lifestyle disorders, and the inclination of the population towards self-administration of drugs. Over the last decade, there has been a rise in the prevalence of several chronic diseases, which in several cases require long hospital stays. Some of the major chronic diseases include cancer, kidney failure, and heart disease, among others. Lifestyle diseases, like hypertension, diabetes mellitus, dyslipidemia, and overweight/obesity, are also becoming major risk factors. For instance, according to GLOBOCAN, in 2020, about 19.3 million new cancer cases were reported worldwide, and this number is expected to reach 30.2 million new cases in the year 2040. This shows a gradual rise in the prevalence of cancer over the forecast period, which is expected to increase demand for needle-free drug delivery devices due to their ease of usage and convenient-administration of drugs. Thus, the increasing patient pool and the increasing prevalence of chronic diseases are anticipated to boost the demand for the market studied.
However, the stringent regulatory framework and limitations associated with the use of micro-needle patches are the few factors restraining the growth of the needle-free drug delivery devices market globally.
Scope of the Report
As per the scope of this report, needle-free drug delivery systems are novel ways to introduce various medicines to patients without piercing the skin with a needle. This method has drastically increased the adoption of important drugs through self-injections. The needle-free drug delivery devices market is segmented by Device Type (Inhalers, Jet Injectors, Novel Needle, Transdermal Patch, and Other Devices), Application (Insulin Delivery, Vaccination, Pain Management, and Other Applications), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
|By Device Type|
Key Market Trends
Insulin Delivery Segment is Expected to Witness Good Growth in Application Segment Over the Forecast Period
The insulin delivery segment is expected to witness significant growth over the forecast period owing to factors such as increasing cases of diabetes and increasing adoption of technologically advanced products.
Diabetes, being a chronic disorder, is a major health concern across the world. For instance, as per the International Diabetes Federation (IDF) Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes globally for 2021, 2030, and 2045 is estimated as 9.8%, 10.8%, and 11.2%, respectively. The demand for need-free insulin delivery devices is expected to increase with the upsurge in the diabetic population and the advantages offered by these devices over other conventional insulin delivery systems such as pens, pumps, and needles. Insulin delivery is typically done via self-administration devices, owing to which the risk associated with the pain and improper drug delivery using sharp objects or needles is high. Needle-free drug delivery devices, on the other hand, are safe and pain-free solutions and can be automated for regular intervals of time. Hence, these advantages offered by the devices are likely to bolster the demand for insulin delivery among the patient population, in turn boosting the market segment’s growth.
Furthermore, company developments with respect to needle-free drug delivery will help in segment expansion. For instance, in June 2022, Transdermal Specialties Global completed a phase 3 clinical trial of a patented transdermal patch using the U-StripTM transdermal insulin delivery system.
Thus, the increasing prevalence of diabetes and the technological advancements in needle-free drug delivery devices are expected to drive the overall growth of the insulin delivery application segment over the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and Expected to do Same in the Forecast Period
The major factors driving the growth of needle-free drug delivery systems in North America are the high awareness among the patient population regarding the availability of novel products available in the market as well as the increasing research and development by the major market players. In addition, the higher prevalence of chronic diseases in the region is expected to have a positive impact on the adoption of needle-free drug delivery devices among the patient population. According to the Alzheimer’s Association, Alzheimer’s Disease Facts and Figures 2022, it is estimated that 6.5 million Americans age 65 and older are living with Alzheimer’s dementia in 2022. Also, according to the National Alliance on Mental Illness report 2020, it is estimated that 1.5 million people annually in the United States are affected by schizophrenia. Both Alzheimer’s and schizophrenia treatments involve the use of multiple drug delivery devices for effective drug administration. Thus, the significant prevalence of the diseases will in turn spur the demand for needle-free devices among the patient population.
Furthermore, strategic developments by key market players will augment the growth of the regional market to a great extent. For instance, in March 2022, Corium, Inc. received approval from the United States Food and Drug Administration (FDA) for ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer's type.
Likewise, in June 2022, NovaXS Biotech, based in the United States, revealed the new prototype for its needle-free injection therapy smart medical device. Telosis, a patent-pending technology from the company, delivers a narrow stream of medication without a needle in 0.3 seconds and evaluates injection data to enable wiser medical choices. The company claimed that its technology offered a simple and painless substitute for at-home medicine delivery, serving as the first remote medication and self-administration monitoring platform. IVF procedures are considered the first indication of NovaXS.
Thus, owing to the above-mentioned factors, the studied market in the North American region is expected to register significant growth over the forecast period.
To understand geography trends, Download Sample Report
The needle-free drug delivery devices market is moderately competitive. The market is currently dominated by innovative companies that are coming up with novel products through the use of technology that reduces the use of needles for drug administration. Some of the companies that currently have a considerable share in the market are Halozyme, Inc. (Antares Pharma.), INJEX Pharma GmbH, 3M, PharmaJet, Mika Medical Co., MannKind Corporation, PenJet, Crossject, Ferring B.V., and Akra Dermojet, among others.
- In May 2022, Halozyme completed its acquisition of Antares Pharma Inc., establishing a leading drug delivery company with numerous potential for licensing its ENHANZE and Antares' auto-injector technology.
- In May 2022, Zealand Pharma A/S entered into an asset purchase agreement with MannKind Corporation to sell the V-Go insulin delivery device for USD 10 million and additional sales-based milestones. V-Go is a once-daily, wearable, patch-like insulin delivery device that helps provide blood sugar control for everyday lifestyles.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
4.2.2 Inclination of Population towards Self-administration of Drugs
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.3.2 Limitations Associated with the Use of Micro-Needle Patches
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Device Type
5.1.2 Jet Injectors
5.1.3 Novel Needle
5.1.4 Transdermal Patch
5.1.5 Other Devices
5.2 By Application
5.2.1 Insulin Delivery
5.2.3 Pain Management
5.2.4 Other Applications
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.3.5 South America
220.127.116.11 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Halozyme, Inc. (Antares Pharma.)
6.1.2 INJEX Pharma GmbH
6.1.5 Mika Medical Co.
6.1.6 MannKind Corporation.
6.1.9 Akra Dermojet
6.1.10 Ferring B.V.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Needle-Free Drug Delivery Devices Market market is studied from 2019 - 2027.
What is the growth rate of Needle-Free Drug Delivery Devices Market?
The Needle-Free Drug Delivery Devices Market is growing at a CAGR of 6.5% over the next 5 years.
Which region has highest growth rate in Needle-Free Drug Delivery Devices Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Needle-Free Drug Delivery Devices Market?
North America holds highest share in 2021.
Who are the key players in Needle-Free Drug Delivery Devices Market?
PharmaJet, INJEX Pharma GmbH, 3M, Halozyme, Inc. (Antares Pharma.), MannKind Corporation. are the major companies operating in Needle-Free Drug Delivery Devices Market.